|
業務類別
|
Biotechnology |
|
業務概覽
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
| 公司地址
| 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037 |
| 電話號碼
| +1 202 734-3400 |
| 傳真號碼
| +1 202 296-1450 |
| 公司網頁
| https://www.vandapharma.com |
| 員工數量
| 533 |
| Mr. Scott Laverne Howell |
Vice President and Chief People Officer |
-- |
23/04/2026 |
| Dr. Mihael Hristos Polymeropoulos,M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 965.66K |
23/04/2026 |
| Mr. Gunther Birznieks |
Senior Vice President, Business Development |
美元 559.94K |
23/04/2026 |
| Mr. Joakim Wijkstrom |
Senior Vice President and Chief Marketing Officer |
美元 579.60K |
23/04/2026 |
| Mr. Kevin Moran |
Senior Vice President, Principal Accounting Officer, Chief Financial Officer and Treasurer |
美元 559.94K |
23/04/2026 |
| Mr. Christos Vasilios Mihael Polymeropoulos, M.D. |
Senior Vice President and Director, Medical |
-- |
23/04/2026 |
|
|
| Dr. Charles C. Duncan, PhD |
Independent Director |
22/04/2026 |
| Dr. Mihael Hristos Polymeropoulos,M.D. |
Chairman of the Board, President and Chief Executive Officer |
23/04/2026 |
| Mr. Richard W. Dugan |
Lead Independent Director |
23/04/2026 |
| Ms. Phaedra S. Chrousos |
Independent Director |
23/04/2026 |
| Ms. Anne Sempowski Ward |
Independent Director |
23/04/2026 |
| Dr. Stephen Ray Mitchell, M.B.A.,M.D. |
Independent Director |
23/04/2026 |
| Dr. Tage Honore, D.Sc.,PhD |
Independent Director |
23/04/2026 |
|
|
|
|
